Evidence map›Paper›PMID 34008877›Full record

ArticleLasers in surgery and medicine2021

Safety and Efficacy of Nano-Pulse Stimulation Treatment of Non-Genital, Cutaneous Warts (Verrucae).

Richard Nuccitelli, Brenda M LaTowsky, Edward Lain, Girish Munavalli, Lesley Loss, E Victor Ross, Lauren Jauregui, William A Knape

Open access · hybridAbstract read
In one paragraph

Article in Lasers in surgery and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Richard NuccitelliPulse Biosciences, 3957 Point Eden Way, Hayward, California, 94545.ORCID 0000-0002-1089-3194
Brenda M LaTowskyClear Dermatology and Aesthetics Center, 20201N. Scottsdale Healthcare Dr. #260, Scottsdale, Arizona, 85255.
Edward LainSanova Dermatology, 1601 E Pflugerville Pkwy,Bldg 1 Ste 1102, Pflugerville, Texas, 78660.
Girish MunavalliDermatology, Laser & Vein Specialists, 1918 Randolph Rd., Charlotte, North Carolina, 28207.
Lesley LossDermatology Associates, 100 White Spruce Blvd, Rochester, New York, 14623.
E Victor RossScripps Clinic, 3811 Valley Centre Dr., San Diego, California, 92130.ORCID 0000-0002-0923-3578
Lauren JaureguiPulse Biosciences, 3957 Point Eden Way, Hayward, California, 94545.
William A KnapePulse Biosciences, 3957 Point Eden Way, Hayward, California, 94545.
Pulse Biosciences (United States) · USDermatology, Laser & Vein Specialists of the Carolinas · USDermatology Surgery & Laser Center · USScottsdale Community College · USScripps Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThis study describes the effects of nano-pulse stimulation (NPS) technology on the common verruca with the objectives of demonstrating efficacy and safety. NPS technology applies nanosecond pulses of non-thermal electrical energy to induce highly localized regulated cell death in the cellular structures of the targeted zone with negligible effects on surrounding non-cellular structures. Previous clinical studies applying NPS to common, benign skin lesions have demonstrated safety and efficacy in clearing seborrheic keratoses and sebaceous hyperplasia. STUDY DESIGN/MATERIALS AND

methodsSixty-two subjects were enrolled at a total of five sites. One hundred and ninety-five study verrucae up to 10 mm wide were treated with NPS delivered by a console-based handheld applicator (CellFX® System; Pulse Biosciences) and follow-ups occurred every 30 days with the option to retreat at 30, 60, and 90 days. There were 62 untreated controls and 46% of the treated verrucae were recalcitrant.

resultsOverall, 75.3% (70/93) of the common verrucae, 72.7% (8/11) of the flat verrucae, and 43.8% (14/32) of the plantar verrucae treated with NPS were completely clear by 60 days following the last treatment and did not recur within the 120-day observation period. The majority (54%) of verrucae cleared with a single NPS procedure. The most common treatment site reactions were erythema (50.5%) and eschar formation (23.4%) on Day 30 and on Day 120 mild erythema was present in 14% of the cases and hyperpigmentation in 18.5%. No serious adverse events were reported. A particle counter was used during 11 NPS procedures on verrucae and no significant plume generation was detected during these procedures.

conclusionsNPS is a safe and effective procedure for removing non-genital, cutaneous verrucae. Lasers Surg. Med. © 2021 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.

Indexed as

Skin DiseasesWartsHumansSkincutaneous verrucaenano-pulse stimulationnanosecondpulsed electric fieldswarts

Identifiers

PMID34008877
PMCPMC9291480
OpenAlexW3162671259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.